Alexander Kurz

Alexander Kurz

Auto-generated profile, based on publicly available information

Alexander Kurz

Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Technische Universität München, Munich, Germany

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2017 in JMIR Rehabilitation and Assistive Technologies
Verified
Journal Article
Open access
FMFranka Meiland
Franka Meiland
AIAnthea Innes
Anthea Innes
GMGail Mountain
Gail Mountain
Louise RobinsonLouise Robinson
Louise Robinson
HRHenriëtte G. Van der Roest
Henriëtte G. Van der Roest
Manuel Franco-MartinManuel Franco-Martin
Manuel Franco-Martin
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

17 July 2008 in International Journal of Geriatric Psychiatry
Verified
Journal Article
Closed access
PDF file
AKAlexander Kurz
Alexander Kurz
CPCorina Pohl
Corina Pohl
MRMichaela Ramsenthaler
Michaela Ramsenthaler
CSChristian Sorg
Christian Sorg

1 June 2009
Verified
Journal Article
Closed access
HHHarald Hampel
Harald Hampel
MEMichael Ewers
Michael Ewers
KBKatharina Bürger
Katharina Bürger
PAPeter Annas
Peter Annas
AMAnette Mörtberg
Anette Mörtberg
HBHans Basun
Hans Basun

1 July 2012 in Alzheimer Disease & Associated Disorders
Verified
Journal Article
Closed access
AKAlexander Kurz
Alexander Kurz
ATAngelika Thöne-Otto
Angelika Thöne-Otto
BCBarbara Cramer
Barbara Cramer
SESilvia Egert
Silvia Egert
LFLutz Frölich
Lutz Frölich
KWKatja Werheid
Katja Werheid
Cognitive rehabilitation (CR) is a promising treatment approach for older adults with dementia because it aims at supporting the management of day-to-day problems. There is insufficient evidence regarding whether CR provides clinically meaningful benefits. In this study, we evaluated the feasibility, acceptance, efficacy, and usefulness of a CR intervention in a multicenter, randomized, controlled trial on 201 patients with mild dementia in Alzheimer disease and their carers. The intervention comprised 12 individual weekly sessions and combined 4 established strategies adopted from neurorehabilitation and psychotherapy. Activities of daily living were chosen as the primary outcome. The results show that the feasibility, treatment adherence, and carer commitment were excellent. However, no effect of the intervention was demonstrable on everyday functioning. There were improvements favoring the intervention on quality of life and treatment satisfaction and a significant antidepressant effect in female participants. The lack of impact on everyday activities may be due to methodological limitations including insufficient personalization, short treatment duration, poor transfer into the real-life setting, and low sensitivity of assessment instruments. The findings of this study may be helpful for designing further studies that are needed to determine the potential of CR in older adults with dementia.

1 March 2011 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
AKAlexander Kurz
Alexander Kurz
RPRobert Perneczky
Robert Perneczky

10 October 2017 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
LFLutz FROELICH
Lutz FROELICH
OPOliver Peters
Oliver Peters
PLPiotr Lewczuk
Piotr Lewczuk
OGOliver Gruber
Oliver Gruber
STStefan J Teipel
Stefan J Teipel
JKJohannes Konrhuber
Johannes Konrhuber
The progression of mild cognitive impairment (MCI) to Alzheimer’s disease (AD) dementia can be predicted by cognitive, neuroimaging, and cerebrospinal fluid (CSF) markers. Since most biomarkers reveal complementary information, a combination of biomarkers may increase the predictive power. We investigated which combination of the Mini-Mental State Examination (MMSE), Clinical Dementia Rating (CDR)-sum-of-boxes, the word list delayed free recall from the Consortium to Establish a Registry of Dementia (CERAD) test battery, hippocampal volume (HCV), amyloid-beta1–42 (Aβ42), amyloid-beta1–40 (Aβ40) levels, the ratio of Aβ42/Aβ40, phosphorylated tau, and total tau (t-Tau) levels in the CSF best predicted a short-term conversion from MCI to AD dementia. We used 115 complete datasets from MCI patients of the “Dementia Competence Network”, a German multicenter cohort study with annual follow-up up to 3 years. MCI was broadly defined to include amnestic and nonamnestic syndromes. Variables known to predict progression in MCI patients were selected a priori. Nine individual predictors were compared by receiver operating characteristic (ROC) curve analysis. ROC curves of the five best two-, three-, and four-parameter combinations were analyzed for significant superiority by a bootstrapping wrapper around a support vector machine with linear kernel. The incremental value of combinations was tested for statistical significance by comparing the specificities of the different classifiers at a given sensitivity of 85%. Out of 115 subjects, 28 (24.3%) with MCI progressed to AD dementia within a mean follow-up period of 25.5 months. At baseline, MCI-AD patients were no different from stable MCI in age and gender distribution, but had lower educational attainment. All single biomarkers were significantly different between the two groups at baseline. ROC curves of the individual predictors gave areas under the curve (AUC) between 0.66 and 0.77, and all single predictors were statistically superior to Aβ40. The AUC of the two-parameter combinations ranged from 0.77 to 0.81. The three-parameter combinations ranged from AUC 0.80–0.83, and the four-parameter combination from AUC 0.81–0.82. None of the predictor combinations was significantly superior to the two best single predictors (HCV and t-Tau). When maximizing the AUC differences by fixing sensitivity at 85%, the two- to four-parameter combinations were superior to HCV alone. A combination of two biomarkers of neurodegeneration (e.g., HCV and t-Tau) is not superior over the single parameters in identifying patients with MCI who are most likely to progress to AD dementia, although there is a gradual increase in the statistical measures across increasing biomarker combinations. This may have implications for clinical diagnosis and for selecting subjects for participation in clinical trials.